- Home
- AITR vs ALVR Comparison
AITR vs ALVR Comparison
Compare AITR & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AITR
- ALVR
- Stock Information
- Founded
- AITR 2022
- ALVR 2013
- Country
- AITR United States
- ALVR United States
- Employees
- AITR N/A
- ALVR N/A
- Industry
- AITR
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AITR
- ALVR Health Care
- Exchange
- AITR Nasdaq
- ALVR Nasdaq
- Market Cap
- AITR 82.6M
- ALVR 87.7M
- IPO Year
- AITR 2023
- ALVR 2020
- Fundamental
- Price
- AITR $10.54
- ALVR $0.94
- Analyst Decision
- AITR
- ALVR Sell
- Analyst Count
- AITR 0
- ALVR 5
- Target Price
- AITR N/A
- ALVR $1.00
- AVG Volume (30 Days)
- AITR 71.3K
- ALVR 155.6K
- Earning Date
- AITR 01-01-0001
- ALVR 11-04-2024
- Dividend Yield
- AITR N/A
- ALVR N/A
- EPS Growth
- AITR N/A
- ALVR N/A
- EPS
- AITR N/A
- ALVR N/A
- Revenue
- AITR N/A
- ALVR N/A
- Revenue This Year
- AITR N/A
- ALVR N/A
- Revenue Next Year
- AITR N/A
- ALVR N/A
- P/E Ratio
- AITR N/A
- ALVR N/A
- Revenue Growth
- AITR N/A
- ALVR N/A
- 52 Week Low
- AITR $10.11
- ALVR $0.58
- 52 Week High
- AITR $10.57
- ALVR $2.49
- Technical
- Relative Strength Index (RSI)
- AITR 78.43
- ALVR 69.10
- Support Level
- AITR $10.51
- ALVR $0.74
- Resistance Level
- AITR $10.57
- ALVR $0.91
- Average True Range (ATR)
- AITR 0.01
- ALVR 0.06
- MACD
- AITR -0.00
- ALVR 0.01
- Stochastic Oscillator
- AITR 83.33
- ALVR 94.50
About AITR AI TRANSPORTATION ACQUISITION CORP Ordinary shares
AI Transportation Acquisition Corp is a blank check company.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.